Synopsis: The FDA-approved dosage of anti-CTLA-4, with and without GM-CSF, was tested on patients with melanoma. Although the antitumor action was equivalent in all groups, the toxic side effects were reduced when GM-CSF was present. Synopsis: Therapeutic PD-1/PD-L1 blockade requires preexisting tumor-infiltrating T cells. In a subset of metastatic RCC patients, antiangiogenic therapy increased T-cell infiltration and PD-L1 upregulation, increasing the likelihood that they may uniquely benefit from combination checkpoint and antiangiogenic therapy.
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Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model Lei Wang, Zohreh Amoozgar, Jing Huang, Mohammad H. Saleh, Deyin Xing, Sandra Orsulic, and Michael S. Goldberg Synopsis: A mechanistic basis for the synergy between decitabine and anti-CTLA-4 was found. This provides a rationale for initiating trials of combination therapy in ovarian cancer, in which many patients do not benefit from immune checkpoint blockade alone. 
ABOUT THE MASTER
Pramod Kumar Srivastava, PhD, MD, is the Northeast Utilities Chair Professor in Experimental Oncology, professor of immunology and medicine, and director of the Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut School of Medicine in Farmington, CT. Dr. Srivastava has championed the cause of personalized immunotherapy of human cancer for over 25 years. He was the first to demonstrate that immunization of mice with heat-shock proteins (HSP) hsp70 and hsp90 isolated from tumors elicited tumor-specific immunity, and that immunogenicity of tumor-derived HSPs comes from HSP-associated peptides, which include any antigenic peptides. He suggested and showed that hsp70 and hsp90 members play a critical role in antigen processing and presentation by MHC class I molecules. Dr. Srivastava showed that endogenous HSPpeptide complexes are the essential vehicles of antigen transfer from antigen-donor cells to antigen-presenting cells (APC) during cross-priming. To explain the powerful adjuvant-like properties of hsp70 and hsp90, he hypothesized and later showed that these HSPs interact with APCs through HSP receptors, such as CD91. Dr. Srivastava developed the HSP-peptide cancer vaccine vitespen or Oncophage, which was approved in Russia in 2008 for treatment of patients with nonmetastatic renal cell carcinoma. Oncophage is the first therapeutic cancer vaccine to be approved for clinical use in the world. An NIH/CTEP (Cancer Therapy Evaluation Program)-approved large randomized study testing Oncophage in patients with recurrent glioblastoma multiforme is ongoing at multiple U.S. centers.
Dr. Srivastava hypothesized in 1993 that cancers are individually antigenically distinct because of random passenger mutations, a proportion of which become immunogenic in any given patient. With the availability of high-throughput genomics and bioinformatics capabilities, he and others have demonstrated that this is indeed the case. Dr. Srivastava is now pursuing genomics-driven personalized immunotherapy for the treatment of human ovarian and other cancers.
Dr. Srivastava has had continuous research support from the NIH for 25 years. He was a member of the NIH Experimental Immunology Study Section and several study sections of the U.S. Department of Defense. He has been a member of the Scientific Advisory Council of the Cancer Research Institute since 1995. In 1997 he was inducted into the Roll of Honor of the Union Internationale Contre le Cancer and became a founding member of the Academy of Cancer Immunology. Dr. Srivastava is an inventor on over 200 awarded patents and has cofounded a number of biotechnology companies, including Antigenics (AGEN), Ikonisys, and Life Science Pharmaceuticals.
Dr. Srivastava obtained his bachelor's degree in biology and chemistry and a master's degree in botany (paleontology) from the University of Allahabad, India. He studied yeast genetics at Osaka University, Japan, and completed his PhD in biochemistry at the Center for Cellular and Molecular Biology, Hyderabad, India. He also trained at Yale University and Sloan Kettering Institute for Cancer Research. He obtained his MD degree from the University of Connecticut School of Medicine. He has previously held faculty positions at the Mount Sinai School of Medicine and Fordham University, both in New York City.
ABOUT THE COVER
With normal cell division comes some genetic infidelity, and this is often exaggerated in cancer cells because of both error-prone replication and exposure to mutagens. Most mutations (represented by upper-case letters in the illustration) go unnoticed and are termed passenger mutations, but occasionally a slight growth or survival advantage is bestowed by the change. Mutations in exons can create neoepitopes, that is, new amino acids or protein conformations that may be visible to the immune system. As these accumulate, they are passed down the line. A tumor mass eventually comprises multiple neoepitope lineages, each expressing different accumulations of neoepitopes, diverging slightly from each other and from the original "mother" cell. Recognition of the role that these neoepitopes can play in cancer immunotherapy has engendered promising new insights and approaches to the treatment of tumors. See the Masters in Immunology article by Pramod K. To request permission to re-use all or part of this article, contact the AACR Publications Department at
